PF-07832837 for Eczema
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called PF-07832837 for individuals with moderate to severe eczema (also known as atopic dermatitis) to assess its safety and effects on the body. Researchers aim to determine if the treatment can reduce eczema symptoms by comparing it to a placebo (a harmless pill with no active drug). The trial suits those who have had eczema for at least a year and have not responded well to topical treatments. Participants must also be generally healthy aside from their eczema. As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in people.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, if you are taking medications for other inflammatory skin diseases or have had recent skin infections, you may need to discuss this with the trial team.
Is there any evidence suggesting that PF-07832837 is likely to be safe for humans?
Research shows that PF-07832837 is being tested for safety and tolerance in humans for the first time. Participants will take one or more doses to observe bodily reactions. As this is an early stage of testing, no safety information from previous studies exists. The main goal is to determine safety and identify any side effects.
In this initial phase, researchers are gathering safety data on PF-07832837. This stage ensures the treatment does not cause harmful reactions. If deemed safe, it may proceed to further testing. Currently, the priority is to ensure it does not harm healthy individuals or those with eczema.12345Why do researchers think this study treatment might be promising for eczema?
Unlike the standard eczema treatments that often involve topical steroids or immunosuppressants like tacrolimus, PF-07832837 is unique because it targets specific pathways involved in the inflammatory process. Researchers are excited about PF-07832837 because it might offer a new mechanism of action that could provide relief without the side effects commonly associated with steroids. Additionally, this treatment is designed to be taken in single or multiple doses, which might offer more flexibility and convenience for patients. The potential for a new, targeted approach could mean better, more sustainable management of eczema symptoms.
What evidence suggests that PF-07832837 might be an effective treatment for eczema?
Researchers are investigating PF-07832837 as a potential treatment for moderate to severe eczema, also known as atopic dermatitis. In this trial, participants will receive either PF-07832837 or a placebo to evaluate the treatment's effectiveness. Specific results are not yet available, but the treatment is being tested for its ability to relieve eczema symptoms. Early studies examine the drug's mechanism in the body and its safety. The goal is to determine if there are improvements in the skin condition of people with eczema. Researchers hope that PF-07832837 will provide a new way to manage this challenging skin condition.13678
Who Is on the Research Team?
Pfizer CT.gov Call Center
Principal Investigator
Pfizer
Are You a Good Fit for This Trial?
This trial is for healthy adults aged 18-55 (Part 1) and those with moderate to severe atopic dermatitis aged 18-70 (Part 2), who have a BMI of 17.5 to 40 kg/m2 and weigh over 50 kg. Participants should either not respond well to topical treatments or cannot use them due to side effects.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment - Single Ascending Dose (SAD)
Participants receive single ascending doses of PF-07832837 or placebo to evaluate safety, tolerability, and pharmacokinetics
Treatment - Multiple Ascending Dose (MAD)
Participants receive multiple ascending doses of PF-07832837 or placebo to evaluate safety, tolerability, and pharmacokinetics
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- PF-07832837
Trial Overview
The study tests PF-07832837, a new medication, against a placebo in both healthy participants and those with atopic dermatitis. It aims to assess the drug's safety, how it's processed by the body, dosage levels, and its effect on skin condition symptoms.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
single or multiple doses of PF-07832837 at ascending dose levels
single or multiple doses of placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Pfizer
Lead Sponsor
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University
Citations
FIH Study to Evaluate the Tolerability of PF-07832837 in ...
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy ...
2.
pfizerclinicaltrials.com
pfizerclinicaltrials.com/find-a-trial/nct06564389-healthy-participants-trialClinical Trial for Healthy Participants and Atopic Dermatitis.
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy ...
3.
theglobeandmail.com
theglobeandmail.com/investing/markets/stocks/PFE/pressreleases/33354319/pfizers-new-phase-1-study-a-potential-game-changer-for-atopic-dermatitis/Pfizer's New Phase 1 Study: A Potential Game-Changer for ...
' The study aims to assess the safety, tolerability, and pharmacokinetics of PF-07832837 in healthy individuals and those with moderate to severe atopic ...
4.
cdn.pfizer.com
cdn.pfizer.com/pfizercom/product-pipeline/Q4%202024%20Pipeline%20Update_vFINAL2_0.pdf?VersionId=Dy5cqrx7ADEzdrB9ULhaUhsm1egolQ2ePfizer Pipeline
Pfizer announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal ...
FIH Study to Evaluate the Tolerability of PF-07832837 in
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy ...
6.
tipranks.com
tipranks.com/news/company-announcements/pfizers-new-phase-1-study-a-potential-game-changer-in-atopic-dermatitis-treatmentPfizer's New Phase 1 Study: A Potential Game-Changer in ...
' The study aims to assess the safety, tolerability, and pharmacokinetics of PF-07832837 in both healthy individuals and those with moderate to ...
7.
theglobeandmail.com
theglobeandmail.com/investing/markets/stocks/PFE/pressreleases/34204447/pfizers-new-phase-1-study-on-pf-07832837-a-potential-game-changer-for-atopic-dermatitis/Pfizer's New Phase 1 Study on PF-07832837: A Potential ...
' The study aims to assess the safety, tolerability, and pharmacokinetics of PF-07832837 in both healthy adults and patients with moderate to ...
PF-07832837 - Drug Targets, Indications, Patents
A phase 1, first in human, randomized, double-blind, sponsoropen, placebo-controlled, single- and multiple dose escalation, parallel group study.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.